The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Akebia Therapeutics Inc (NASDAQ: AKBA) closed at $1.69 down -12.44% from its previous closing price of $1.93. In other words, the price has decreased by -$12.44 from its previous closing price. On the day, 9.6 million shares were traded. AKBA stock price reached its highest trading level at $1.84 during the session, while it also had its lowest trading level at $1.525.
Ratios:
For a deeper understanding of Akebia Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.21 and its Current Ratio is at 1.52.
On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.
Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 03 ’25 when Butler John P. sold 46,409 shares for $1.83 per share. The transaction valued at 84,928 led to the insider holds 2,557,921 shares of the business.
Burke Steven Keith sold 7,144 shares of AKBA for $13,074 on Mar 03 ’25. The SVP, Chief Medical Officer now owns 809,090 shares after completing the transaction at $1.83 per share. On Mar 03 ’25, another insider, Burke Steven Keith, who serves as the Officer of the company, bought 7,144 shares for $1.83 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 368725888 and an Enterprise Value of 490267712. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.17. Its current Enterprise Value per Revenue stands at 2.886 whereas that against EBITDA is 111.172.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.86, which has changed by -0.0058823824 over the last 52 weeks, in comparison to a change of 0.07903516 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $2.48, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is -15.77%, while the 200-Day Moving Average is calculated to be 6.22%.
Shares Statistics:
For the past three months, AKBA has traded an average of 2.25M shares per day and 3134020 over the past ten days. A total of 211.54M shares are outstanding, with a floating share count of 209.23M. Insiders hold about 4.10% of the company’s shares, while institutions hold 28.71% stake in the company. Shares short for AKBA as of 1740700800 were 14879018 with a Short Ratio of 6.62, compared to 1738281600 on 14453171. Therefore, it implies a Short% of Shares Outstanding of 14879018 and a Short% of Float of 6.890000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Current recommendations for the stock of the company come from 1.0 analysts. The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.04 and -$0.04 for the fiscal current year, implying an average EPS of -$0.04. EPS for the following year is $0.09, with 2.0 analysts recommending between $0.38 and -$0.2.
Revenue Estimates
A total of 2 analysts believe the company’s revenue will be $44.04M this quarter.It ranges from a high estimate of $46.28M to a low estimate of $41.8M. As of the current estimate, Akebia Therapeutics Inc’s year-ago sales were $32.61MFor the next quarter, 2 analysts are estimating revenue of $42.93M. There is a high estimate of $43.8M for the next quarter, whereas the lowest estimate is $42.05M.
A total of 3 analysts have provided revenue estimates for AKBA’s current fiscal year. The highest revenue estimate was $224.46M, while the lowest revenue estimate was $176.9M, resulting in an average revenue estimate of $192.77M. In the same quarter a year ago, actual revenue was $160.18MBased on 2 analysts’ estimates, the company’s revenue will be $307.05M in the next fiscal year. The high estimate is $365.33M and the low estimate is $248.78M.
